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I 
Bone Morphogenetic Protein 4 
regulates white, beige and brown 
adipose tissue 
Jenny Hoffmann 
Department of Molecular and Clinical Medicine, Institute of Medicine 
Sahlgrenska Academy at University of Gothenburg 
Göteborg, Sweden 
ABSTRACT 
Obesity and its associated complications, including Type 2 diabetes, are 
increasing at an epidemic rate globally. Adipose tissue exerts different 
functions and is central in energy homeostasis, and it consists of white, beige 
or brown adipocytes. White adipocytes (in white adipose tissue, WAT) store 
and release lipids while brown adipocytes (in brown adipose tissue, BAT), 
oxidize lipids and generate heat. Beige adipocytes reside in WAT, appear white 
but can oxidize lipids upon stimulation (browning). The aim of this thesis was 
to investigate the role of Bone Morphogenetic Protein 4 (BMP4) in white, 
beige and brown fat. In Paper I, we used human WAT biopsies and precursor 
cells. In Paper II and III, we gave adult mice adeno-associated viral (AAV) 
vectors to increase circulating BMP4. Endogenous BMP4 is increased in WAT 
in obesity, and so are BMP antagonists, resulting in reduced BMP4 signalling. 
WAT browning was enhanced by increasing BMP4 signalling in human 
precursor cells and in WAT of lean mice. Surprisingly, BAT activity was 
inhibited in the mice, but whole-body energy expenditure was increased which 
protected from obesity. However, AAV BMP4 did not enhance browning of 
WAT in initially obese mice, likely due to the cellular BMP4 resistance. 
Additionally, all AAV BMP4-treated mice had increased insulin sensitivity. In 
summary, BMP4 is an important regulator of white, beige and brown fat. 
BMP4 increases in WAT in obesity but its positive effects are antagonized by 
the BMP antagonists. However, increasing BMP4 signalling can prevent 
obesity by browning WAT and also increase insulin sensitivity making it an 
interesting novel therapeutic target. 
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II 
SAMMANFATTNING PÅ SVENSKA 
Fetma ökar i världen som en konsekvens av att vi rör oss mindre och får i oss 
mer kalorier. Fetma är associerat med negativa hälsoeffekter såsom typ 2 
diabetes, hjärt-kärl sjukdom mm. Fettvävnaden är viktig då det är där vi ska 
lagra energiöverskott. Underhudsfettet är det primära området att expandera, 
om vi inte kan expandera det kommer fett lagras i buken, i levern och i muskler, 
vilket är associerat med negativa hälsoeffekter. En ytterligare central aspekt är 
att alla fettceller inte är lika. Det finns tre typer fettceller; vita fettceller 
lagrar/frisätter fett, bruna fettceller förbränner fett och producerar värme och 
beigea fettceller finns i den vita fettvävnaden men kan börja förbränna fett vid 
aktivering. Aktivering av beigea fettceller har visat sig ha stor potential i 
musstudier där det skyddar mot viktökning. 
Den här avhandlingen är fokuserad på proteinet Bone Morphogenetic Protein 
4 (BMP4) och hur det reglerar vitt, beige och brunt fett. I den första artikeln 
använde vi humana fettbiopsier och i de två sista artiklarna använde vi möss 
som fick BMP4-genterapi. De viktigaste fynden är:  
• Ökad BMP4 signalering gör vita fettceller beigea med ökad 
förbränning, både i humana celler samt i smala möss. När vi 
sen matade mössen med foder med högt fettinnehåll var de 
skyddade mot viktökning. 
• Fetma är associerat med förhöjda nivåer av eget BMP4 
protein, både hos möss och människor, och även ökade nivåer 
av BMP antagonister (som förhindrar signalen) i den vita 
fettvävnaden. Detta resulterar i att effekten av eget BMP4 
försämras, d.v.s. en BMP4-resistens. 
• BMP4 ökar insulinkänsligheten hos möss, som vanligtvis är 
försämrad vid fetma. Denna effekt är oberoende av att 
fettcellerna blir mer beigea. 
Sammantaget så visar vi att genom att öka BMP4 signalen i vitt fett så kan vi 
göra fettceller beigea och därmed öka förbränningen, samt förbättra 
insulinkänsligheten. Ökad förståelse av BMP4-signalering i fett kan leda till 
nya terapeutiska möjligheter vid fetma och typ 2 diabetes. 
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1 INTRODUCTION 
1.1 Prevalence of obesity 
Obesity is, in the vast majority of cases, caused by the imbalance between 
calories consumed and calories expended. The prevalence of obesity is 
increasing due to an increased intake of energy-dense foods and an increase in 
physical inactivity. Worldwide, obesity has more than doubled since 1980 
according to the World Health Organization (WHO). For adults, WHO defines; 
overweight as a BMI greater than or equal to 25 and obesity as a BMI greater 
than or equal to 30. According to the WHO, 39% of adults aged 18 years and 
over were overweight in 2014 and 13% were obese. 
1.2 Obesity, the Metabolic syndrome and 
Type 2 diabetes 
Obesity is tightly associated with development of the MetS, which is a 
constellation of related metabolic risk factors that increase the risk for CVD 
and T2D, and some forms of cancer [1, 2]. The most widely recognized 
metabolic risk factors are elevated blood glucose, lipids (dyslipidemia) and 
elevated blood pressure, and patients usually have increased circulating levels 
of pro-inflammatory markers [1]. The underlying risk factors, driving the 
development of these metabolic risk factors, appear to be IR and ectopic fat 
accumulation in different tissues [1]. The association with fat distribution will 
be discussed in detail below. 
Compared to non-obese, overweight/obese individuals have a 3.5-4.6/10.0-
11.2 relative risk of developing T2D over a 10-year period [2]. Other 
etiological risk factors are age, family history of T2D, and physical inactivity, 
but populations with the highest prevalence of T2D also have the highest 
prevalence for obesity [3]. Briefly, T2D can develop following IR, and IR is a 
state of impaired insulin sensitivity. Insulin sensitivity is the capacity of target 
cells to respond to insulin and lower blood glucose. The major insulin-sensitive 
tissues are fat, skeletal muscle and liver [4], and the effects of insulin are 
summarized in Figure 1. Insulin activation of signalling leads to suppression 
of hepatic glucose production, and increased hepatic lipogenesis and glycogen 
synthesis. In skeletal muscle, insulin signalling leads to increased glucose 
uptake and glycogen synthesis. In fat, insulin signalling increases glucose 
uptake and lipogenesis, and reduces lipolysis. The specific actions in fat are 
discussed below. Obesity and dyslipidemia may lead to lipids accumulating 
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ectopically in skeletal muscle and liver, which leads to reduced insulin 
sensitivity in these target cells. The pancreatic ?-cells, which sense glucose 
levels, will produce more insulin to compensate for the peripheral tissue IR 
and T2D develops when the ?-cells fail to produce enough insulin [5, 6].  
 
 
 
 
 
 
 
 
 
 
There is evidence for the contribution of genetics in the risk of developing 
T2D. A number of genetic risk variants have been shown to contribute to T2D 
risk [7]. However, the individual effect of these variants is modest and, 
together, they can account for approximately 10% of the disease prediction [3]. 
Yet, we and others have demonstrated that genetic predisposition for T2D, 
defined as being a FDR, is associated with reduced insulin sensitivity also in 
lean adults [8, 9], and that FDRs exhibit a dysfunctional WAT associated with 
impaired insulin sensitivity [8]. Furthermore, around 30% of obese individuals 
are metabolically healthy [10] and, on the contrary, around the same 
percentage of lean individuals are metabolically unhealthy with reduced 
insulin sensitivity [11]. Thus, BMI per se is not a sufficiently sensitive marker 
of individual risk for developing T2D. WAT distribution has emerged as an 
additional important measure and this is further discussed below. 
 
Figure 1. Overview of insulin actions in target tissues. 
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1.3 WAT and white adipocytes 
Adipose tissue can be broadly divided into two distinct types, WAT and BAT. 
Additionally, in the last couple of years, a third type called 
beige/brite/recruitable brown adipocytes have emerged as a separate type. The 
characteristics of the different tissues/cells are discussed in the following 
sections. 
1.3.1 WAT distribution 
The SubQ WAT is the largest fat depot in man and is also the preferable site 
to store excess fat. Expansion of the visceral WAT depot has a clear association 
to MetS. Although increased BMI itself is a risk factor for IR and T2D, for any 
given amount of total body-fat, an individual with increased visceral fat is at 
greater risk for developing IR and its consequences [12]. The SubQ WAT does 
not show this association, and some studies have actually shown it to be 
inversely correlated with MetS disease risk [13]. 
The SubQ WAT has a limited expandability. When the SubQ WAT storage 
capacity is exceeded, fat is stored in ectopic sites like the visceral depot, 
skeletal muscle and liver, driving IR. Safe storage of lipids in the SubQ depot 
has been demonstrated in several mouse models. Over-expression of 
adiponectin in fat of obese mice leads to healthy expansion of the SubQ fat 
with complete rescue of the diabetic phenotype, demonstrating the clear 
benefits of “shunting” lipid storage to the SubQ depot over ectopic storage 
[14]. The limit for when the SubQ fat storage capacity is reached varies greatly 
between individuals and is likely determined by both genetic and 
environmental factors [15]. There is also a gender difference in the capacity to 
expand the SubQ WAT as females maintain a greater capacity to recruit new 
adipocytes in the lower-body region as adults [16] and obese women have 
reduced ectopic visceral fat compared to obese men [17]. Visceral obesity 
correlates strongly with IR and individuals with IR, not necessarily obese, 
commonly have increased visceral fat [12, 18]. Taken together, fat distribution 
is an important determinant for the risk of developing MetS. 
1.3.2 Hypertrophic adipose cell expansion 
WAT can expand through two separate events, either through enlargement of 
existing adipocytes (hypertrophic expansion) or by differentiation of new 
adipocytes from precursor cells (hyperplastic expansion). Hypertrophic, rather 
than hyperplastic expansion, is associated with IR and dyslipidemia for a given 
BMI [19, 20]. Reduced ability to recruit new adipocytes leads to an 
inappropriate, hypertrophic expansion of existing adipocytes and this is a 
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typical trait of high-risk individuals with a family history of T2D; FDRs [21]. 
This expansion is associated with adipose tissue fibrosis, infiltration and 
activation of pro-inflammatory immune cells, local and systemic IR, increased 
lipolysis and altered adipokine secretion [22, 23]. Furthermore, hypertrophic 
obesity is closely associated with expansion of the visceral fat depot, IR and 
T2D [24]. These events are summarized in Figure 2. 
 
 
 
 
 
 
 
 
 
 
1.3.3 White adipogenesis 
White adipocytes have a MSC origin, and MSCs provide a reservoir for 
adipose precursor cells, which can proliferate and differentiate into mature 
adipocytes [25]. Commitment and differentiation of white adipocytes is a 
complex process and all events are not yet known. One of the earliest events 
in the commitment of MSCs into the adipocyte lineage is repression of ZFP521 
[26]. ZFP521 acts upstream of the PPARg transcriptional activator ZFP423 
and inhibits its expression by repressing early B-cell factor 1 (EBF1) [27]. 
BMP4 is an important commitment factor into the white adipose lineage [25, 
28], and in Paper I we show that BMP4 is secreted by mature adipocytes, 
probably as a positive feed-back regulator to recruit new adipocytes. ZFP423 
is translocated to the nucleus following BMP4 activation and signalling [29]. 
Also EBF1 is localized to the nucleus and, together, EBF1 and ZFP423 activate 
PPARg, the master regulator of adipogenesis [29, 30]. This event commits the 
cells to the adipose lineage. Following PPARg activation, several transcription 
Figure 2. Characteristics of adipocyte hypertrophy. Adipocyte expansion 
with dysregulated subcutaneous (SubQ) fat promotes ectopic fat 
accumulation and the MetS. Adipocyte hypertrophy characterizes the SubQ 
fat of insulin-resistant obesity. Adapted from [31]. 
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factors are activated such as C/EBPb, d and a and several genes inhibiting 
adipogenesis are repressed [31]. Once expressed, PPARg and C/EBPa act in a 
positive feedback loop to maintain expression and drive terminal 
differentiation, including adipocyte-specific genes such as Fabp4, Glut4 and 
adiponectin, and induce cellular insulin sensitivity and lipid accumulation [31].  
1.3.4 Lipid storage and release 
Main functions of the white adipocytes are storage of energy, as TAG, and 
release of energy, as FFAs. In the fed state, adipocytes take up FFAs from the 
circulation via fatty acid transporters and glucose is taken up through GLUTs 
[32, 33]. TAG synthesis requires both glucose and FFAs and synthetized TAG 
is stored in lipid droplets [34, 35]. When energy substrates are needed, TAGs 
are hydrolyzed to glycerol and FFAs (lipolysis) to allow FFAs to reach other 
tissues [33]. Catecholamines (e.g. epinephrine) stimulate lipolysis through β-
adrenergic signalling which increases cAMP and Protein Kinase A activity 
leading to increased lipolysis [33]. The three major lipolytic lipases are ATGL 
(the main TAG lipase), HSL (the main diacylglycerol lipase) and 
monoacylglycerol lipase [33]. Insulin, on the other hand, inhibits lipolysis, 
acting at several different levels [33]. Insulin-resistant adipocytes have 
increased lipolysis, resulting in increased circulating FFA levels, which 
contribute to ectopic lipid accumulation and IR in other tissues as discussed 
above.  
1.3.5 Adipokine secretion 
Another important function of the white adipocytes is secretion of adipokines 
with a wide range of functions that signal locally or systemically. Two of the 
best characterized adipokines are leptin and adiponectin. Leptin was 
discovered in 1994 and its discovery gave WAT a role also as an endocrine 
organ as circulating leptin signals centrally to reduce food intake [36, 37]. 
Leptin levels are increased in obesity and correspond to body fat mass [37]. 
Adiponectin is also secreted by mature adipocytes but is negatively correlated 
with fat mass. It is a well-established marker of insulin sensitivity and it exerts 
several different effects promoting metabolic health [36, 37]. Obese, 
adiponectin over-expressing mice have an improved diabetic phenotype, and 
reduced fat- and systemic inflammation (due to the healthy expansion of the 
SubQ WAT) [14]. A large class of adipokines are the immunoregulatory 
proteins. In the obese, hypertrophic state, adipocytes secrete pro-inflammatory 
cytokines like Tumor necrosis factor (TNF)a and IL6, promoting a local 
proinflammatory state, recruitment of proinflammatory immune cells and  
secretion of proinflammatory factors into the circulation [23]. In addition, 
TNFa and IL6 can directly induce IR in adipocytes [38]. 
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1.3.6 Insulin-stimulated glucose uptake 
The insulin signalling pathway that mediates glucose uptake is schematically 
depicted in Figure 3. Insulin receptor signalling is initiated by the binding of 
insulin to the extracellular α-subunits of the insulin receptor, which leads to 
auto-phosphorylation of the β-subunits and subsequent phosphorylation of 
Insulin receptor substrates (IRSs) [39]. IRS1 and 2 function as docking 
proteins recruiting and activating phosphoinositide 3-kinase (PI3K), leading to 
the generation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) [39]. 
Membrane-bound PIP3 recruits and activates 3-phosphoinositide-dependent 
protein kinase 1 (PDK1), which phosphorylates and activates Protein Kinase 
B (PKB/AKT) [39]. However PIP3 can also directly activate AKT [4, 39]. 
AKT phosphorylates TBC1 Domain Family Member 1 (TBC1D1) and 
AS160/TBC1D4 which mediate glucose uptake through increased GLUT4 
translocation to the membrane [39, 40]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overview of the insulin signalling pathway. Insulin receptor 
substrate 1, 2 (IRS1, IRS2), phosphoinositide 3-kinase (PI3K), 
phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 3,4,5-
trisphosphate (PIP3), 3-phosphoinositide-dependent protein kinase 1 
(PDK1), protein kinase B (PKB/AKT), TBC1 domain family member 1, 4 
(TBC1D1, AS160/TBC1D4), glucose transporter 4 (GLUT4). 
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1.4 BAT and brown adipocytes 
BAT consists of specialized, brown adipocytes which greatly differ from white 
adipocytes and are derived from stem cells able to differentiate into both brown 
adipose cells and skeletal muscles [41]. Brown adipocytes have a multilocular 
phenotype, contain numerous mitochondria, and have the capacity to burn 
glucose and fat to produce heat. Figure 4a and b show the different appearances 
of white (a) and brown (b) adipocytes. Figure 4c and d show beige adipocytes, 
which will be described in the next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Electron micrographs demonstrate the characteristic 
appearances of different mouse adipose tissue depots. White adipocytes in 
subcutaneous (SubQ) white adipose tissue (WAT) contain a single lipid 
droplet (a). Brown adipocytes in brown adipose tissue contain multilocular 
lipid droplets (b). Browning leads to formation of islets of multilocular 
beige adipocytes within SubQ WAT (c), with increased mitochondrial 
content (d). Scale bars: a–c, 50 μm; d, 1μm. a-c are adapted from [66],  
d: SubQ WAT from AAV BMP4 mice, Cohort 2, Paper II. 
d
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The thermogenic function of brown adipocytes is mediated by the key protein 
UCP1, which allows uncoupled oxidation meaning that, in addition to 
generating adenosine triphosphate (ATP), UCP1 allows the proton gradient to 
flow back over the inner mitochondrial membrane resulting in heat generation 
[42]. BAT is present only in mammals, and in rodents, BAT is an essential 
organ throughout life [43]. Rodent BAT is located in distinct depots in the neck 
region. Humans are also born with substantial amounts of BAT in the neck-
region but, commonly, BAT is lost with age. Rodent BAT and the BAT that 
humans are born with is often referred to as classical BAT (as compared to 
beige fat or recruitable BAT that is described below). It was not until 2009 that 
evidence emerged for the presence of active, UCP1-positive BAT also in adult 
humans [44-46] in the neck- and spinal region of patients examined with 
Positron Emission Tomography (PET) scans, albeit this BAT seems to differ 
from the classical BAT (further discussed below). Regardless, as BAT has the 
capacity to oxidize lipids instead of storing them, the potential of increasing 
numbers or activity of brown adipocytes is of great interest. The presence of 
BAT in adult man was found to be inversely correlated with age, BMI and 
circulating glucose levels suggesting the potential metabolic relevance of BAT 
in adults [44]. 
1.5 Beige adipocytes 
In addition to white and brown adipocytes, a separate third variant, the 
beige/brite or recruitable brown adipocyte, has been described in the last 
couple of years in rodents [42, 47, 48]. It has been known for many years that 
some rodent WAT depots contain cells with a brown adipocyte appearance 
(UCP1 expression and multilocular phenotype) following cold-stimulation or 
pathways that increase cAMP [49]. The beige adipocytes appear white under 
basal conditions, have low basal UCP1 expression but have the capacity to 
induce UCP1 upon stimulation and oxidize lipids and drive thermogenesis [47, 
48]. As the activity of beige adipocytes is inducible, and a number of recent 
mouse models have shown that induction of beige adipocytes are linked to 
improved metabolic health [50-52], beige adipocytes are gaining a lot of 
research interest. Figure 4 shows beige adipocytes in SubQ WAT (c-d) 
compared to white (a) and brown (b) adipocytes in mice. 
1.5.1 De novo differentiation or transdifferentiation? 
As opposed to white or classical brown adipocytes, the origin of beige 
adipocytes is debated in the literature. Generally, beige adipocytes are assumed 
not to share the Myogenic factor 5 (Myf5)-developmental lineage with 
classical, rodent brown adipocytes [41]. However recent results indicate that 
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there are some adipocytes also in WAT depots that have the Myf5-
developmental origin [53]. Furthermore, the debate concerns whether beige 
adipocytes emerge following de novo differentiation, i.e. that they are a unique, 
committed cell type that undergo beige differentiation following stimuli, or if 
they are transdifferentiated, mature white adipocytes. Both ideas are supported 
in the literature. 
In support of the de novo differentiation hypothesis, it was shown in 2012 that 
beige adipocytes arise from a separate population of isolated and cloned WAT-
derived precursor cells [47]. These cells had unique marker genes 
distinguishing them from typical white or brown adipocytes and only the beige 
WAT-derived clones could induced UCP1. Moreover, the brown preadipocyte 
marker Ebf2 has been found in a specific subset of SubQ WAT-derived 
precursor cells, and only this subset underwent browning following stimulation 
[54]. Furthermore, experiments using genetic adiponectin-driven labelling of 
adipocytes in vivo, showed that cold- or β-adrenergic agonist induced 
browning occurs to a great extent through de novo differentiation of (beige) 
precursor cells rather than transdifferentiation of mature white adipocytes [55].  
On the other hand, several groups have provided evidence in favor of the 
transdifferentiation hypothesis. Also by using adiponectin-labelling of 
adipocytes in vivo, it was shown that cold exposure drives browning in SubQ 
WAT from mature white adipocytes through transdifferentiation [56]. 
Additionally, it has been shown that there is  no or only a small change in DNA 
content or adipocyte number during browning of WAT, and that most beige 
adipocytes are derived from non-dividing cells in fat which makes the mature 
adipocytes the most probable source [57-60]. 
Altogether, the literature provides evidence that both sources of cells may 
contribute to browning of WAT. Interestingly, it has been shown that beige 
adipocytes lose their UCP1 expression, but remain in WAT during warm 
adaptation with a white-like morphology. In a second cold exposure, these cells 
can again induce UCP1 expression [61]. This study may suggest that the extent 
of beige cell recruitment through transdifferentiation or de novo differentiation 
may be dependent on the environmental history and/or age of the mouse. 
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1.5.2 Human brown/beige fat 
Human infants are born with BAT that shares morphological and molecular 
characteristics of the classical, rodent BAT [62]. In adults, however, BAT is 
generally composed of both white and brown adipocytes and the gene 
expression pattern resembles more the rodent beige adipocytes than the 
classical, rodent brown adipocytes [47, 63, 64], although some studies have 
shown that adults do have classical BAT in some regions [65, 66]. In adults 
who initially lacked detectable BAT, prolonged cold exposure increases BAT 
activity in the neck region, which was associated with a decrease in body fat 
mass [67]. Given the inducible nature of rodent beige fat, it is likely that what 
we today call human BAT is more beige than brown. 
1.6 Bone Morphogenetic Proteins 
1.6.1 BMPs in development 
BMPs are members of the Transforming growth factor beta (TGFb)-
superfamily. Today, there are over 20 known BMPs [68] and the protein family 
was originally named after its ability to induce ectopic bone formation. BMPs 
have crucial and wide roles during development, e.g. dorsoventral patterning 
during embryogenesis involves incremental levels of BMP-2/4 and of BMP 
antagonists, which restrict cells to specific developmental lineages [25]. Also 
at later stages, BMPs are involved in tissue development and maintenance [69].  
1.6.2 BMP signalling 
BMPs are synthesized as precursor proteins with an N-terminal signal peptide, 
a prodomain for folding and secretion and a C-terminal mature protein. BMPs 
are cleaved to generate the mature proteins, which dimerize and interact with 
the receptors [69, 70]. BMPs can signal both through Smad-dependent and 
Smad-independent pathways. In the Smad-dependent pathway, BMPs bind cell 
surface receptors aggregated in a heterotetrameric complex, comprised of two 
type 1 receptor subunits and two type 2 receptor subunits [69]. When BMP 
ligands bind the receptor complex, the constitutively active type 2 receptors 
phosphorylate the intracellular domain of the type 1 receptors which will then 
phosphorylate the downstream substrate proteins; the receptor-regulated 
Smads (R-Smads). The R-Smads involved in BMP signalling are R-Smad1, 5 
and 8. R-Smads associate with the co-mediator Smad (co-Smad) 4, and the 
complex translocates to the nucleus and regulates transcription [69, 71].  
Ligand binding to BMP Receptor 1a (BMPR1a) is also able to initiate Smad-
independent pathways, such as the p38 mitogen-activated protein kinases 
 (MAPK) signalling pathway. Briefly, the adapter protein X-linked inhibitor of 
apoptosis protein (XIAP) binds the receptor and allows binding of the TGFb 
activated kinase 1 (TAK1) and TGFb activated binding protein (TAB1), 
allowing subsequent activation of p38 MAPK and regulation of gene 
expression [68, 69, 71]. Mammalian cells have four different p38 MAPKs, 
initially described as transducers of stress responses (such as inflammation), 
but have since then been shown to be activated also following various non-
stress stimuli [72]. The Smad-dependent and the Smad-independent pathways 
are summarized in Figure 5.  
BMPs signal through three different type 1 receptors: BMPR1a (ALK3), 
BMPR1b (ALK6) and type 1A activing receptor (ActR1A or ALK2), and three 
different type 2 receptors: BMPR2, type 2 activin receptor A and B (ActR2A, 
2B) [69]. The mechanism of receptor complex formation is intricate and varies 
with the BMP ligands, and a number of co-receptors and antagonists are also 
regulating the signal [68, 69]. 
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Figure 5. Overview of Smad dependent and Smad independent Bone 
Morphogenetic Protein (BMP) signalling pathways. X-linked inhibitor of 
apoptosis protein (XIAP), TGF-b activated binding protein (TAB1), TGF-
b activated kinase (TAK1), p38 mitogen-activated protein kinase (p38). 
Adapted from [71]. 
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1.6.3 BMP4 in adipogenesis 
BMP4 is crucial for white adipogenesis. It is a key regulator of commitment of 
precursor cells into the white adipocyte lineage [28, 73, 74] by allowing 
nuclear localization of ZFP423 and Pparg activation [29]. BMP4 treatment of 
WAT SVF cells leads to a robust increase in adipocyte gene expression 
demonstrating their adipogenic commitment, shown in Paper I and in earlier 
work from our lab [74]. Moreover, in hypertrophic WAT, characterized by an 
impaired recruitment of precursor cells, adding BMP4 to the cultured precursor 
cells rescues adipogenesis [74]. In Paper I and in our earlier work, we have 
also shown that BMP4 is expressed and secreted by mature white adipocytes 
[74], likely as a signal to uncommitted cells to undergo adipogenic 
differentiation, thereby enhancing lipid storage capacity and preventing the 
development of a dysregulated hypertrophic expansion. 
In addition to driving white adipogenesis, there is a growing body of evidence 
that BMP4 is also involved in the development of beige adipocytes. In a mouse 
MSC line, BMP4-treatment during adipogenic differentiation induced a beige 
phenotype and implantation of BMP4-treated MSCs into WAT in mice gave 
rise to UCP1-positive adipocytes [75]. Furthermore, transgenic mice, over-
expressing BMP4 in the adipose tissue, had increased browning of WAT [50]. 
Likewise, in Paper II of this thesis, we show that lean mice undergoing BMP4 
gene therapy had increased browning of WAT, increased energy expenditure 
and were protected against obesity. Also, in Paper I, we show that adding 
BMP4 and/or silencing the BMP antagonist Gremlin1 in human adipose 
precursor cells increases UCP1 and mitochondria. Similar effects of BMP4 on 
human adipose precursor cells have also been shown elsewhere [76]. 
Additionally, it was recently shown that BMP4 treatment of differentiating 
mouse brown preadipocytes in vitro led to increased lipid accumulation and a 
decreased brown fat-phenotype, and this was further confirmed in vivo with 
impaired BAT function following adenovirus BMP4-treatment [77]. The 
negative effect of BMP4 on BAT function and lipolysis was also seen in the 
BMP4 gene therapy-treated mice in Paper II. 
1.6.4 BMP4 in obesity 
Elevated circulating BMP4 levels are seen in obesity, and appear to be further 
increased in individuals with impaired glucose tolerance and T2D [77]. This 
study also shows increased circulating BMP4 in individuals with hypertrophic 
obesity, in agreement with our findings in Paper I. Specific genetic variants of 
the BMP receptors BMPR1A and BMPR2 are associated with obesity in man 
[78-80]. In this thesis, we introduce the concept of BMP4 resistance in obesity. 
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In Paper I, we found BMP4 secretion to be increased by differentiated 
hypertrophic human adipocytes. However, the effect of BMP4 was regulated 
by the secreted BMP antagonist Gremlin1 which was also increased. The 
findings in Paper I are in agreement with our findings in mice in Papers II and 
III where endogenous Bmp4 is increased in WAT of obese mice. However, we 
show that in mice, it is the BMP antagonist Noggin that is increased with 
obesity (rather than Gremlin1 in human cells), and both the expression of Bmp4 
and Noggin were associated with markers of IR. 
1.6.5 p38 MAPK in adipogenesis 
Increased p38 MAPK signalling following BMP-stimulation has been implied 
to play a role in adipogenesis in MSCs and in 3T3-L1 cells [50, 81]. However, 
it is currently not clear if increased p38 MAPK signalling is beneficial or not 
for adipogenesis. p38 MAPK activity is important for proper 3T3-L1 
differentiation and Pparg activation is impaired when p38 MAPK is inhibited 
[82, 83]. In other reports, using isolated mouse preadipocytes, the inhibition of 
p38 MAPK was beneficial for adipogenesis as p38 MAPK inhibits C/ebpb and 
Pparg expression in those cells [84]. In brown adipocytes from mice, cAMP-
induced activation of p38 MAPK was shown to induce PGC1a and UCP1 and 
p38 MAPK activation was actually suggested to be necessary for the cold-
induction of UCP1 [85]. Increased p38 MAPK signalling was also the 
proposed mechanism behind the increased browning of WAT in the fat-
specific BMP4 over-expressing mice [50]. In Paper III, we show increased p38 
MAPK signalling in WAT following BMP4 gene therapy, together with a 
phenotype of enhanced adipose cell terminal differentiation and insulin 
signalling. However, short-term incubation of adipose cells with BMP4 did not 
increase p38 MAPK. Thus, we cannot conclude that the phenotype is a result 
of increased p38 MAPK signalling by BMP4. 
1.7 Adeno-associated viral vector mediated 
gene therapy 
WT AAVs are naturally occurring viruses but until recently they have not been 
a topic of interest due to the lack of pathogenicity without a helper virus [86]. 
However, the understanding of AAVs potential in gene therapy has sparked 
much interest. WT AAVs integrate in the genome, however the recombinant 
AAV vectors are designed to lack the gene responsible for integration and are, 
therefore, unable to integrate in the host genome and remain inside the cell 
preferentially as episomes [87]. They are also replication deficient, and other 
attractive traits of the AAV vectors are their structural simplicity, low 
inflammatory response and their capacity to deliver transgenes into targeted 
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post-mitotic host cells and to drive this transgene expression for an extended 
period of time [88]. AAV vectors exist in 11 different serotypes, with different 
tropism. Serotype two is the best characterized and serotype eight has the 
greatest liver transduction efficiency [89]. In Papers II and III we used AAV 
vectors of serotype eight to target the liver of the mice. The effectiveness of 
AAV vector gene therapy is becoming more and more well-characterized [90-
92] and they are also used in a number of clinical trials. Briefly, AAV vectors 
have been used in humans to transduce cells in the retina [93], the central 
nervous system [94, 95], the liver [96], skeletal- [97] and cardiac muscle [98].  
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2 AIMS 
The over-all aim of this thesis was to investigate the effect of BMP4 on white, 
beige and brown fat and the effect of BMP4 gene therapy on phenotype and 
metabolism in mature mouse models in vivo. 
In Paper I we aimed to characterize the effect of BMP4 in regulating white and 
beige adipogenesis in human WAT precursor cells in vitro and its relation to 
obesity and adipose cell size of the donors. 
In Paper II we aimed to examine the effects of BMP4 gene therapy in mature 
mouse models including effects on development of obesity, whole-body 
insulin sensitivity, energy expenditure and browning of WAT. 
In Paper III we aimed to examine the possible effect of BMP4 gene therapy in 
treating, rather than preventing, obesity in mice. 
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3 METHODS 
3.1 Ethical statement 
The Ethical Committee of the University of Gothenburg approved the study 
design and written informed consent was received from study participants prior 
to inclusion in the study. Likewise, approval from the local Ethics Committee 
for Animal Studies at the Administrative Court of Appeals in Gothenburg was 
obtained prior to performing any animal experiments. 
3.2 Tissue donors and samples 
The human material used in Paper I was biopsies, isolated adipocytes and 
precursor cells from SubQ WAT. The material was obtained through needle 
biopsies from the abdominal SubQ depot of the study participants, except for 
one biopsy that was obtained through bariatric surgery. All subjects had normal 
glucose levels and had no known chronic disease. In Papers II and III, male 
C57BL6/N mice were purchased from Taconic. They were group caged, 
maintained on a 12 hour light-dark cycle in a temperature-controlled facility 
(+21oC), and had ad libitum access to food and water. During studies, the mice 
were fed either HFD (45 kcal% fat) or nutrient-matched CD (10 kcal% fat). 
3.3 The AAV BMP4 mouse model 
3.3.1 AAV vector-mediated, liver-specific BMP4 over-
expression 
In this mouse model, which was used in Paper II and III, the goal was to deliver 
the Bmp4 transgene to the liver to have BMP4 protein secreted and reach target 
tissues. We used recombinant AAV vectors of serotype eight and the transgene 
expression was under control of the human Alpha 1-Antitrypsin (hAAT1) 
promoter, a combination described previously [90]. The AAV vectors were 
produced in the laboratory of Fatima Bosch, with the method described briefly 
in Papers II and III and in referenced literature [99]. For the control mice, an 
empty AAV vector was produced. The AAV vectors were mainly delivered 
intravenously and subsequently reached the liver. However, the AAV vectors 
were injected retro-orbitally in Cohort 1 in Paper II but all other animals had 
tail vein-injections. All mice received 5 x 1011 viral particles/200 ul 
saline/mouse. Upon termination, we verified that the vectors induced BMP4 in 
the liver and increased circulating BMP4 levels. Thus, the BMP4 over- 
expression was stable for the full duration of the study. 
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3.3.2 Metabolic phenotyping 
The mice in Paper II and III underwent weighing and food intake was recorded. 
Metabolic phenotyping was performed as described below. Upon termination, 
the mice were euthanized using isofluorane. Blood was collected through heart 
puncture for analysis of metabolites. Tissues were weighed and either snap 
frozen in liquid nitrogen, fixed in 4% formaldehyde or incubated in sterile 
Hank’s balanced salts medium prior to digestion (WAT only, method 
described below). 
Glucose- and insulin tolerance tests 
A GTT was performed to assess the systemic clearance of glucose (determined 
by insulin secretion and action). Briefly, a bolus dose of glucose is given by 
I.P. injection, and blood glucose and insulin levels are monitored before and 
repeatedly during the test [100]. During the ITT, a bolus dose of insulin is given 
by I.P. injection and blood glucose levels are monitored before and repeatedly 
during the test. The decrease of blood glucose during the ITT shows the 
systemic insulin sensitivity [100]. Both tests were performed following 4 hours 
fasting. More specific details of the tests are given in Paper II and III.  
Body composition 
Analysis of body composition, through measurement of total body fat, lean 
body mass and bone mineral density and –content was performed using a 
DEXA [101] (Paper II). 
Indirect calorimetry 
O2 consumption, CO2 production and activity were assessed through an 
Indirect Calorimetry analysis using the SOMEDIC Metabolic System [102]. 
Briefly, O2 consumption and CO2 production were calculated by measuring the 
difference in chamber inlet and outlet of gasses. Indirect calorimetry was 
performed on mice in Papers II and III and the values were normalized to body 
weight. A MiniMitter Probe was inserted surgically in the peritoneal cavity of 
the mice, which allowed concurrent monitoring of activity and body 
temperature. The measurements were performed both during the light- and 
dark-phase of the day. More details can be found in Papers II and III. 
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3.4 In vitro experiments 
3.4.1 Isolation of adipocytes, precursor cells and 
their differentiation 
WAT biopsies, both human and mouse, were treated as described in detail in 
Paper I, II and III. Adipocyte cell size was measured as described, and SVF 
cells following WAT digestion were seeded and expanded [38, 74, 103] or 
harvested for gene expression analysis. We performed various treatments and 
transfections. SVF cells were induced to differentiate at passages three to four 
with an adipocyte differentiation cocktail as described [38]. After three days, 
media was replaced with adipocyte maintenance media, renewed every third 
day throughout the differentiation period, and cells were cultured for up to 21 
days for full differentiation. 
3.4.2 Cell respiration 
In Paper II, we measured cell respiration in live cells using an extracellular flux 
analyzer (Seahorse Bioscience; Agilent Technologies). Prior to the analysis, 
primary mouse SubQ WAT preadipocytes were differentiated for seven days 
with and without BMP4 and with and without 24 hours adrenergic stimulation 
with isoproterenol. The cellular respiration analysis yielded data on basal 
respiration, ATP production, uncoupled respiration and maximum respiration 
of the cultured cells. More details can be found in Paper II. 
3.4.3 mRNA analysis 
RNA was isolated from cells or homogenized tissues using commercially 
available kits optimized for the various starting materials. The isolated RNA 
was used to synthesize cDNA for the subsequent qRT-PCR reaction. In all 
Papers, the TaqMan system for qRT-PCR gene expression analysis was used. 
Gene expression of the ribosomal housekeeping gene 18S rRNA was used to 
normalize the data. 
3.4.4 Protein analysis  
Cell and tissue proteins 
Isolated adipocytes were separated from the media by centrifugation through 
dinonyl phthalate oil. Protein lysis buffer was added to cells and tissues, which 
were then rocked at 4oC for 2h. The samples were centrifuged and the 
supernatant, containing the protein lysate, separated and protein concentration 
determined. Specific proteins were separated and analyzed with and without 
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prior immunoprecipitation using conventional immunoblotting procedures in 
all three Papers. 
ELISA 
Serum concentrations of Insulin, Adiponectin and Serum Amyloid A isoform 
3 (SAA3) (Paper II and III), and secreted levels of BMP4 and Gremlin1 during 
preadipocyte differentiation (Paper I) were quantified using ELISA techniques 
as described in the Papers.  
Histology and IHC 
Histology and IHC are commonly used techniques to visualize tissue 
morphology and tissue/cell proteins. The techniques are usually performed on 
fixed samples, commonly using paraformaldehyde which crosslinks proteins 
resulting in increased rigidity of the samples. We used hematoxylin-eosin 
morphology staining in Paper II and III [104]. Additional stainings used were 
Mitotracker staining of mitochondria (Paper I), LipidTOX Red staining of 
lipids (Paper II) and Picosirius Red staining of collagen (Paper II). IHC was 
used for visualization of specific proteins in cells or tissues. Details of the IHC-
techniques used are described in Papers I and II. In Paper II, TEM was 
performed to visualize mitochondria in SubQ WAT, essentially as described 
[105].  
3.5 Statistical analyses 
The experimental data are presented as means ± the standard error of the mean 
(SEM). Student’s t-test or Mann-Whitney non-parametric U-test were used for 
comparisons of two groups and ANOVA was used for comparisons of several 
groups. In Paper I, Students t-test or one-way ANOVA (with Tukeys post-hoc 
test) were used. In Paper II, Students t-test, non-parametric Mann-Whitney U-
test or one-way ANOVA (with Bonferronis post-hoc test) were used where 
indicated. Additionally, Spearman’s nonparametric correlation coefficient was 
used to measure dependence between variables. In Paper III, Students t-test or 
non-parametric Mann-Whitney U-test were used where indicated. Statistics 
were calculated using IBM SPSS Statistics version 20, GraphPad Prism 
version 6.03 for Windows, or Microsoft Excel. P<0.05 was considered 
statistically significant. 
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4 RESULTS 
In this section, the main results from Paper I, II and III are summarized. Details 
of the results can be found in the separate Papers.  
4.1 BMP4 and BMP antagonists regulate 
human white and beige adipogenesis  
(Paper I)  
In Paper I, we characterized the effect of BMP4 and BMP antagonists in 
regulating white and beige adipogenesis in human WAT in relation to obesity. 
We found BMP4 to be induced during adipose cell differentiation, and also 
secreted by differentiated mature adipocytes. Hypertrophic obesity is 
characterized by impaired precursor cell recruitment and, as BMP4 is an 
adipogenic commitment factor, our initial hypothesis was that hypertrophic 
adipose tissue had reduced BMP4 levels. In contrast, BMP4 secretion was 
increased by hypertrophic adipose tissue and correlated positively with 
adipocyte size of the donors. However, the precursor cells exhibited a 
resistance to BMP4 due to increased expression and secretion of the BMP 
antagonist Gremlin1. This was also increased in hypertrophic obesity and 
correlated positively with adipocyte size. Gremlin1 is rapidly down-regulated 
when adipose cell differentiation is initiated in precursor cells and follows the 
same time course as PPARg induction.  
Addition of BMP4, and/or silencing (si)Gremlin1, increased PPARg and 
ZFP423 mRNA, thus indicating a role of Gremlin1 in regulating the 
proadipogenic effects of BMP4. Furthermore, siGremlin1 promoted 
preadipocytes to assume an oxidative beige/brown adipose phenotype with 
increased mitochondrial biogenesis and UCP1. Enhancing white adipose cell 
differentiation inhibited the beige/brown markers but siGremlin1 and/or 
adding BMP4 prior to the white adipose cell differentiation re-activated the 
beige/brown phenotype markers.  
In summary: BMP4 is secreted by mature white adipose cells, likely part of a 
feed-back mechanism to recruit new adipocytes. BMP4 secretion is increased 
in hypertrophic obesity similar to the BMP antagonist Gremlin1, resulting in a 
BMP4 resistance in the adipose precursor cells. BMP4 regulates both white 
and beige adipogenesis. Enhanced BMP4 signalling, either by increased BMP4 
itself and/or by inhibiting the BMP antagonist Gremlin1, promotes  
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beige/brown differentiation. A schematic view of the findings in Paper I are 
summarized in Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic view of the findings in Paper I, on the regulation of 
commitment and differentiation of human subcutaneous adipose precursor 
cells by BMP4 and Gremlin1. BMP4 increases during differentiation and 
exerts effects as a secreted molecule. This effect of BMP4 enhances 
commitment and differentiation of new preadipocytes as a positive feed-
back mechanism to prevent adipose cell hypertrophy. The effect of BMP4 
is regulated by the endogenous BMP inhibitors, and in human adipose cells, 
Gremlin1 regulates the effect of BMP4 on both white and beige/brown 
adipocyte differentiation. Bone Morphogenetic Protein 4 (BMP4), Zinc 
finger protein 423 (ZFP423), Peroxisome proliferator-activated receptor 
gamma (PPARg), Fatty-acid binding protein 4 (FABP4), Uncoupling 
Protein 1 (UCP1), Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC1a). 
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4.2 BMP4 gene therapy in mature mice 
reduces BAT activation but protects from 
obesity by browning subcutaneous adipose 
tissue (Paper II)  
In Paper II, we investigated if we could influence the browning of WAT in 
adult, lean mice through BMP4 gene therapy using AAV BMP4 vectors 
(serotype eight). The vectors targeted the liver and increased hepatic and 
circulating BMP4 levels. Following vector administration, the mice were fed 
CD or HFD for several weeks before phenotyping.  
AAV BMP4 treatment induced pronounced browning of the SubQ WAT, with 
increased number and size of mitochondria, increased UCP1 expression, 
increased whole-body energy expenditure and the mice were protected from 
HFD-induced obesity. BMP4-treated mice fed CD had unchanged body weight 
but, like the HFD-treated mice, improved insulin sensitivity. Furthermore, we 
confirmed our findings of increased browning by BMP4 in differentiating 
mouse SubQ WAT preadipocytes in vitro together with increased respiration. 
There was no change in adipocyte numbers in WAT of the AAV BMP4-treated 
mice, and no increase in endothelial cell markers, supporting that browning of 
WAT following AAV BMP4 treatment is likely a result of transdifferentiation 
of mature adipocytes. 
Unexpectedly, the AAV BMP4 mice had increased lipid accumulation, 
decreased UCP1 and increased expression of white adipose cell genes in BAT 
suggesting that BMP4 treatment impairs BAT function. However, regardless 
of these negative effects in BAT, the AAV BMP4 mice had increased whole-
body energy expenditure which prevented obesity.  
Similar to the results in Paper I, endogenous Bmp4 was increased in WAT of 
obese mice. This was accompanied by increased expression of the BMP 
antagonist Noggin (rather than Gremlin1 as in human WAT). Both Bmp4 and 
Noggin mRNA levels were associated with measures of degree of insulin 
sensitivity supporting BMP4 resistance also in WAT of obese mice.  
In summary: Increased circulating levels of BMP4 in adult, initially lean mice 
prevent HFD-induced obesity and IR through increased browning of SubQ 
WAT combined with increased energy expenditure. In contrast, BMP4 reduces 
BAT activation showing the importance of browning the large SubQ WAT in 
preventing HFD-induced obesity in these mice. Lastly, WAT in obese mice is 
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characterized by BMP4 resistance, similar to what was found in human 
hypertrophic obesity (Paper I) but Noggin, rather than Gremlin1, was increased 
in obese mice. Figure 7 shows a schematic view of the findings in Paper II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic view of the findings in Paper II. Obesity leads to BMP4 
resistance also in mice with increased expression of endogenous BMP4, and 
of the BMP antagonist Noggin. By increasing BMP4 signalling, the 
subcutaneous (SubQ) white adipose tissue (WAT) undergoes browning, 
whereas the brown adipose tissue (BAT) has increased lipid accumulation 
and reduced activity. Despite the effects in BAT, whole-body energy 
expenditure is increased, which is protective against obesity and associated 
consequences. Endogenous (Endo), High fat diet (HFD), Bone 
Morphogenetic Protein 4 (BMP4), Uncoupling Protein 1 (UCP1), 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1a). 
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4.3 BMP4 gene therapy improves insulin 
resistance in obese mice without effects on 
adipose tissue browning or body weight 
(Paper III)  
Based on our findings in Paper II, we examined if AAV BMP4 gene therapy 
in mature mice reduces already established obesity. In this study, we used the 
same AAV BMP4 vectors (serotype eight), in older, HFD-induced obese mice 
who continued on HFD following vector administration. As before, AAV 
BMP4 treatment resulted in increased hepatic and circulating BMP4 levels.  
Interestingly, the positive effects of AAV BMP4 on browning SubQ WAT in 
initially lean mice was not seen in initially obese mice. BMP4 gene therapy did 
not reverse established obesity or increase whole-body energy expenditure. 
However, whole-body insulin sensitivity and glucose tolerance were improved 
despite the lack of effect on body weight. Adipocyte insulin signalling was 
enhanced in the AAV BMP4-treated mice with increased IRS1 protein levels 
and insulin-stimulated pAKT activation. Circulating adiponectin levels were 
also increased which, combined with increased SubQ WAT adiponectin and 
G-protein coupled receptor 120 (Gpr120) mRNA levels, support that BMP4 
enhanced terminal differentiation of the adipocytes. p38 MAPK signalling was 
also increased in SubQ WAT of BMP4-treated mice but this was not 
reproduced by short-term BMP4 incubations in vitro.  
BAT lipid accumulation was increased in both obese groups and there was no 
further increase in lipid accumulation following BMP4 therapy and UCP1 
levels were also unaltered. Thus, obesity by itself produced a similar effect in 
BAT as seen in the lean mice treated with BMP4 in Paper II. mRNA levels of 
endogenous Bmp4 and the BMP antagonist Noggin were increased in both 
SubQ WAT and BAT in the obese mice and pSMAD1/5/8 signalling was 
reduced. Together, these findings further support the concept of adipose tissue 
BMP4 resistance in obesity and that this also includes BAT.  
In summary: Obesity is a state of adipose tissue BMP4 resistance, likely due 
to increased Noggin in mice. There was no change in body weight, browning 
of SubQ WAT or in energy expenditure in initially obese mice receiving AAV 
BMP4 gene therapy. However, BMP4 therapy did increase whole-body insulin 
sensitivity and improved adipose cell insulin signalling. This positive effect of 
BMP4 is apparently not resistant in the SubQ WAT and may be a consequence 
of p38 MAPK activation and/or enhanced adipose cell terminal differentiation. 
The findings in Paper III are summarized in Figure 8.  
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Figure 8. Schematic view of the findings in Paper III. Obesity leads to 
insulin resistance and BMP4 resistance with increased expression of 
endogenous BMP4, and of the BMP antagonist Noggin. BMP4 gene 
therapy given to obese mice does not drive browning of the white adipose 
tissue (WAT), but whole-body glucose tolerance and insulin sensitivity are 
improved. Adiponectin and adipocyte insulin signalling are also increased, 
and so is p38 mitogen-activated protein kinases (p38 MAPK) signalling in 
WAT, suggestive of additional actions of BMP4, independent of browning. 
Endogenous (Endo), High fat diet (HFD), Bone Morphogenetic Protein 4 
(BMP4), Uncoupling Protein 1 (UCP1). 
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5 DISCUSSION 
Obesity and its associated complications are increasing at an epidemic rate, 
which imposes a major economic burden on society and vast impacts on 
quality of life for afflicted individuals. Therefore, increased knowledge to 
develop new therapeutic strategies is warranted. In this thesis, we have studied 
BMP4 and its effects in adipose tissue and the main results are 
comprehensively discussed below. 
5.1 BMP4-induced browning of WAT 
Probably the most important finding in this thesis is the AAV BMP4-induced 
browning of SubQ WAT in lean, mature mice, which increases whole-body 
energy expenditure and is protective against diet-induced obesity. We and 
others have previously shown that BMP4 is an important commitment factor 
for mesenchymal precursor cells into the white adipose lineage and induction 
of PPARg [25, 28, 29, 73, 74]. In this thesis, we show the importance of 
maintained BMP4 signalling under adipogenic differentiation and, in the 
mature SubQ WAT, to direct the adipose cells towards a beige adipocyte 
phenotype. 
WAT browning in rodents occurs through two different mechanisms; either by 
transdifferentiation of existing adipocytes or by de novo recruitment of 
committed adipocytes [42, 55, 61]. When increasing BMP4 signalling during 
in vitro differentiation of human or mouse preadipocytes in Papers I and II, or 
in WAT in adult mice in Paper II, adipocyte development is directed towards 
a beige and oxidative phenotype. Our data show the flexibility during SubQ 
adipocyte differentiation and in the mature SubQ WAT. We do not provide 
firm proof of classical transdifferentiation in the mature mouse models; i.e.; 
BMP4-induced browning of mature adipocytes, since we did not genetically 
label the adipose cells initially. However, we do provide evidence that BMP4 
re-directs preadipocytes towards a beige phenotype in vitro and in mature 
WAT in lean mice with minimal fat expansion when BMP4 is provided long 
after the pool of SubQ adipose precursor cells is established [55]. Moreover, 
we did not find an increased adipocyte number in WAT following browning 
and endothelial/precursor cell markers (indicative of proliferation of precursor 
cells) were unaltered. Taken together, our data strongly support that BMP4 
drives transdifferentiation of white adipocytes to induce browning. 
Surprisingly, when we gave AAV BMP4 vectors to obese mice, we did not 
induce WAT browning or weight loss. Endogenous BMP4 antagonists are 
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increased in the adipose tissue in obesity, which inhibit the effects of BMP4, 
and this is further discussed below. 
Regarding the mechanisms for the AAV BMP4-induced browning, 
sympathetic input was apparently unaltered in WAT (and BAT) following 
AAV BMP4 treatment, which supports a local rather than a central effect of 
BMP4, consistent with recent findings by Modica et al in BAT [77]. 
Importantly, a recent study demonstrated that ZFP423 acts as a molecular 
brake on adipocyte thermogenesis by inhibiting the brown-fat transcription 
factors Ebf2 and PR domain containing 16 (Prdm16) in white adipocytes [106]. 
It was shown that deletion of Zfp423 increased EBF2-mediated browning in 
vivo in mature adipocytes and mice. Additionally, it was shown in vitro that 
ZFP423 and EBF2 form a complex in white adipocytes, which is disrupted by 
BMP7 and BMP4, allowing EBF2 to drive the thermogenic gene program 
[106]. This is a likely and attractive mechanism also in the SubQ WAT of our 
AAV BMP4 mice and experiments to test this hypothesis are currently being 
carried out. 
Today, many mouse models of WAT browning have been described. There are 
three lines of evidence that emphasize that beige adipocytes in rodents do 
contribute to energy expenditure and can protect against weight gain. Firstly, 
a strong correlation between WAT browning potential and susceptibility to 
diet-induced obesity has been identified by using different inbred mouse 
strains [107, 108]. UCP1 levels in classical BAT did not differ between the 
strains, supporting the potential of WAT browning. Secondly, induction of 
beige adipocytes contributes to non-shivering thermogenesis upon ablation of 
BAT, indicating that beige adipocytes compensate when BAT is diminished 
[109]. Lastly, several mouse models with increased browning of WAT are 
protected against diet-induced obesity by activating various signalling 
pathways. The classical model is cold-exposure, where norepinephrine is 
released from the SNS which increases β-adrenergic signalling [42]. Other 
models include transcriptional activators of the brown adipose gene program 
(PRDM16 [110] and Forkhead box C2 [105]), immune pathways (IL-4 [111] 
and IL-33 [112]) and other secreted factors such as fibroblast growth factor 21 
[52], and BMP4 in our AAV BMP4 gene therapy mice. 
Targeting white adipocytes pharmacologically in man to induce browning is 
an intriguing concept. However, the absolute majority of research on WAT 
browning is done in rodents. Human BAT has been proposed to have more in 
common with beige fat, rather than classical BAT, and the presence of human 
BAT is diminished with increasing age and BMI [44, 46, 47, 113]. Browning 
of WAT in man has been described in severe medical conditions and strains 
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such as cancer cachexia [114], following severe burns leading to prolonged 
adrenergic stress [115], and in hyperthyroidism and thyroid hormone treatment 
[116]. It has been shown that subjects who initially lacked active BAT could 
recruit BAT upon moderate, daily cold-exposure, or by ingestion or capsinoids 
(also activating the SNS), and the BAT recruitment was associated with 
decreased body fat mass [67]. Moreover, in Paper I we show that increasing 
BMP4 signalling in human preadipocytes drives a beige phenotype, thus 
confirming that targeting this pathway may become a future therapeutic also 
in man. Importantly, the finding that BMP4 controls browning through direct 
effects on adipose cells, without increased adrenergic stimulation, is beneficial 
from a future therapeutic point-of-view as β-adrenergic mediated weight loss 
in man has proven to be a problematic route [117]. 
5.2 BMP4-induced “whitening” of BAT 
Until recently, BAT was not a known target of BMP4. However, as we and 
others have discovered lately, BMP4 does target BAT as well as WAT. BMP4 
signals through a specific set of receptor isoforms [118] and there is only a 
small difference in their  expression  in white compared to brown preadipocytes 
[119]. Despite the evidence that BMP4 drives browning of WAT, BMP4 
actually impairs  the development of the classical brown phenotype of mouse 
cells in vitro and in vivo by reducing HSL, increasing lipid accumulation and 
disrupting the thermogenic capacity, which results in reduced BAT activity 
and energy expenditure [50, 77]. Interestingly, it was also found that when 
BMP4 was administered systemically, energy expenditure was increased [77]. 
When comparing those results to our mice in Paper II, the phenotypes are 
similar as we found whole-body energy expenditure to be increased following 
AAV BMP4 treatment due to browning of WAT, despite BAT being impaired 
with increased lipids and reduced UCP1. These findings point out two 
important things. Firstly, the effect of BMP4 is cell-type dependent in terms of 
increasing or decreasing the oxidative capacity in primary white or brown 
adipocytes. Secondly, these findings underscore the metabolic potential of 
browning WAT and are in line with the previously mentioned mouse model 
with compensatory browning of WAT upon ablation of BAT [109]. These 
results are important since the majority of adult humans have very little BAT 
and it is largely of a beige rather than classical brown phenotype [47, 64]. 
The opposite effects of BMP4 on WAT and BAT are interesting in light of the 
increased circulating BMP4 levels seen in human obesity as shown in Paper I 
and by others [77, 120]. As BAT is inversely correlated with age and BMI [44], 
increased circulating BMP4 may drive “whitening/beigeing” of BAT during 
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ageing or obesity. This is similar to what we see in BAT from lean AAV 
BMP4-treated mice in Paper II, where increased circulating BMP4 levels 
induce an “obese/beige phenotype” in BAT with increased lipids and 
decreased UCP1. However, as we saw in obese mice in Paper III, increased 
BMP antagonists in obesity may also induce BMP4 resistance in BAT which 
reduces BMP4-mediated “whitening/beigeing” compared to what we saw in 
lean AAV BMP4-treated mice.  
5.3 BMP4 resistance in the adipose tissue in 
obesity 
In this thesis we have introduced the concept of BMP4 resistance in obesity. 
We show that BMP4 is increased in the expanding WAT and it is also increased 
in circulation [77, 120], likely as a positive feed-back mechanism to promote 
recruitment of new adipocytes as BMP4 is an important commitment factor for 
the white adipose lineage [25, 28, 29, 73, 74]. However, we show that 
endogenous BMP antagonists are also increased in WAT in obesity. In man, 
Gremlin1 is increased, whereas in mice Noggin is increased, resulting in 
reduced BMP4 signalling through the Smad1/5/8 pathway. Interestingly, WAT 
mRNA expression and genetic variants of BMPR1a and BMPR2 are associated 
with obesity in man [78, 79]. Very little is known about the regulation and 
functions of the BMP antagonists in mature tissues and in WAT specifically. 
In Paper I, we provide the first evidence, to the best of our knowledge, of their 
regulation in WAT upon weight gain. Gremlin1 is somewhat more well-
characterized than Noggin as it is involved in other pathways, including 
inflammation and fibrosis [121, 122], and in regulating angiogenesis in a BMP-
independent manner [123]. 
In human WAT precursor cells and in WAT in lean mice, maintaining 
functional BMP4 signalling is sufficient to promote browning of WAT. This 
is further supported by the positive effects of silencing Gremlin1 in the human 
WAT precursor cells. To further characterize the effect of AAV BMP4 gene 
therapy, we also treated obese mice but did not see the same effects on   
browning WAT and this was associated with BMP4 resistance defined as 
reduced activation of pSMAD1/5/8 signalling. This is likely explained by the 
increased Noggin levels in both obese groups which antagonize BMP4. 
Additionally, the impaired BAT phenotype that we saw in the BMP4-treated 
non-obese cohort was less different between the obese treated and non-treated 
mice in Paper III. Like in WAT, Noggin levels were increased in BAT in both 
obese groups of mice, suggesting a BMP4 resistance also in BAT in obesity. 
However, it should be emphasized that the BMP4 resistance following BMP4 
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treatment/obesity is relative and pronounced activation of SNS by cold or 
massive β3-adrenergic stimulation clearly activated BAT and reduced the 
lipids. Further studies are required to elucidate if BMP4 regulates peripheral 
adrenergic sensitivity in BAT cells but we did not see any evidence of impaired 
activation of lipolysis by isoproterenol in white adipocytes in Paper II. 
p38 MAPK is another putative down-stream mediator of BMP4 signalling 
[50]. Surprisingly, p38 MAPK signalling was not resistant in obesity, as p38 
MAPK was increased in WAT following AAV BMP4 treatment of obese mice. 
Noggin antagonizes BMP signalling by inhibiting BMP- and receptor-
interaction [124]. However, structural alterations in the BMP receptor complex 
formation allow Smad1/5/8- or p38 MAPK signalling [125], which suggests 
that Noggin acts at the level of inhibiting the Smad1/5/8 pathway specifically 
and allowing p38 MAPK signalling. 
Based on these findings, we suggest that as a future therapeutic to increase 
WAT browning and energy expenditure in obesity, it is more strategic to target 
and reduce Gremlin1 in WAT, rather than increasing overall BMP4 signalling.  
Moreover, p38 MAPK signalling is not resistant and increased BMP4 is 
sufficient to induce the specific insulin-sensitizing effects also in obese mice. 
5.4 BMP- and insulin signalling 
Throughout all the cohorts, the AAV BMP4 mice have increased insulin 
sensitivity compared to controls. In the HFD-fed AAV BMP4 mice in Paper 
II, the large difference in body weight is a major confounder for the improved 
glucose homeostasis. However, both the CD-fed, lean AAV BMP4 mice in 
Paper II and the obese mice in Paper III have increased whole-body insulin 
sensitivity, despite similar body weights as their controls. This indicates that 
the improved insulin sensitivity is independent of, and not secondary to, weight 
loss following browning of WAT. The increased insulin sensitivity was also 
observed in HFD-fed transgenic mice over-expressing BMP4 in the adipose 
tissue and with similar body weights as the WT control mice [50]. In the lean, 
AAV BMP4-treated mice in Paper II, and in the transgenic BMP4-mice [50], 
one can speculate that the improved insulin sensitivity is caused by increased 
glucose uptake by beige or brown adipocytes. Cold-activation increases 
glucose uptake in BAT [126], which may also be the case upon browning of 
WAT. However, the obese mice in Paper III do not have increased browning, 
yet the mice have a clearly improved whole-body insulin sensitivity and 
glucose tolerance indicating other insulin sensitizing pathway(s). Furthermore, 
the obese AAV BMP4 mice had improved insulin signalling in adipocytes, 
increased markers of adipocyte differentiation, and increased circulating 
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adiponectin, an established marker of insulin sensitivity and metabolic health 
[127]. It should be added that we also did not see any differences in GLUT4 
expression in cells from mice treated with BMP4.  
Additional evidence for crosstalk between the BMP- and insulin signalling 
pathways has been reported. BMP7-treatment of MSCs leads to a coordinated 
regulation of several components of the insulin signalling pathway [128]. 
Recently, it was shown that ablation of BMPR1a in fat improves age-related 
insulin resistance in mice [129]. These data are somewhat contradictory to 
ours, as ablation of BMPR1a decreases BMP signalling, whereas we increased 
BMP4 signalling in our mice. However, ablation of BMPR1a caused a BMP-
mediated change in immune cell infiltration in fat promoting the insulin 
sensitive phenotype [129] while we did not see any differences in markers of 
the immune-phenotype in fat in our mice.   
p38 MAPK is a downstream target of BMP4 and p38 MAPK has also been 
proposed as a target in IR. Increasing p38 MAPK in skeletal muscle has 
positive effects on insulin-stimulated glucose uptake [130, 131], and activation 
of p38 MAPK in the liver of obese mice enhances blood glucose regulation 
[132], supporting a role of p38 MAPK in antagonizing IR. However, we cannot 
conclude that the increased insulin sensitivity is a direct result of increased 
BMP4/p38 MAPK signalling. We did not see any direct effects by short-term 
BMP4 incubations in vitro on the p38 MAPK- or insulin signalling pathways, 
but this may require longer exposure times and/or different BMP4 
concentrations. p38 MAPK has also been implicated in adipogenesis, both as 
a positive and negative factor depending on context [82-84]. One can speculate 
that long-term BMP4 stimulation in vivo targets p38 MAPK improving 
adipocyte terminal differentiation, which is reduced in obesity and associated 
with IR [38]. This is supported by our finding of increased expression of other 
markers of terminal differentiation of the adipose cells including adiponectin 
and Gpr120.  Taken together, our results support a crosstalk between BMP4- 
and insulin signalling, either directly or via enhanced terminal adipocyte 
differentiation, and these observations warrant further investigations. 
5.5 Other BMPs also regulate metabolism 
Also other BMPs than BMP4 are involved in regulating adipose tissue and 
metabolism. BMP2 is, similar to BMP4, a commitment factor for the white 
adipose lineage [133]. BMP8B increases BAT thermogenesis both locally and 
when administered centrally and knock-out mice have reduced metabolic rate 
which causes weight gain [134]. BMP7 regulates brown adipogenesis and 
increases energy expenditure [119]. Recently, also BMP3b and BMP9 have 
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been implied in browning of WAT [135, 136]. In addition to regulating brown 
adipogenesis directly, BMP7 has central effects in suppressing food intake 
[137]. However, in the same experimental setting, it was shown that BMP2, 
which in many ways resembles BMP4, did not have a direct effect on appetite-
regulation [137]. The lean, AAV BMP4-treated mice in Paper II had increased 
food intake. However, we strongly favor this to be secondary to the increased 
energy expenditure. When the browning-phenotype is lost in the obese AAV 
BMP4 mice in Paper III, food intake is also unaltered supporting the important 
role of the increased energy expenditure. This is also in line with the above-
mentioned data regarding BMP2 [137]. 
5.6 AAV-mediated gene therapy 
We here used a gene therapy approach, with AAV vectors that increase 
circulating BMP4 in adult mice. AAV-mediated gene therapy is efficient in 
long-term gene transfer in animal models [90-92] and it has also been used in 
clinical trials for human diseases [93-98]. Regarding animal models in 
research, AAV-mediated gene therapy has several benefits. Firstly, vector 
administration is easy, and it is less time- and mouse-consuming compared to 
the use of transgenic mice. Secondly, by targeting a specific tissue in adult 
mice, one reduces the risk of confounding results at several levels. The vectors 
are administered at a specific time-point, which gives clear results and avoids 
early developmental effects. Our AAV BMP4 mice received vectors as adult 
mice, making the observed phenotype also more interesting from a therapeutic 
point-of-view compared to genetically manipulated models. Additionally, 
gene expression of the AAV vector delivered transgene is controlled by a cell- 
or tissue- specific promotor, which provides additional control of the transgene 
expression. We think that the gene therapy models we have developed here, 
using mature animals, provide important insight into the potentials of BMP4 
signalling and action as targets for therapy in human obesity and T2D.     
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6 CONCLUSION 
Taken together, we show that BMP4 and its antagonists are important 
regulators of beige, white and brown adipose tissue. BMP4 secretion is 
increased in WAT in obesity but its effect is antagonized by the induction of 
endogenous BMP inhibitors; Gremlin1 in man and Noggin in mice. These 
inhibitors are increased in hypertrophic obesity and may contribute to this 
development by inhibiting commitment of adipogenic precursor cells. BMP4 
gene therapy in adult, initially lean mice leads to increased circulating levels 
of BMP4, browning of WAT, increased whole-body energy expenditure and 
prevention of HFD-induced obesity. However, obesity is a state of adipose 
tissue BMP4 resistance, and BMP4 gene therapy does not enhance browning 
of WAT when given to initially obese mice. Yet, WAT terminal differentiation 
may be enhanced since adiponectin levels are increased. Importantly, we also 
found that BAT activation is antagonized by BMP4 leading to a more beige, 
less metabolically active phenotype as also seen in human BAT in obesity. 
Taken together, the current results suggest the possibility that the association 
between obesity and impaired BAT activation seen in human studies may be a 
consequence of the increased BMP4 secretion by WAT leading to the impaired 
BAT activation and its assumption of a beige phenotype rather than impaired 
BAT activation leading to obesity in man. 
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